Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.
EP. 1: Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia
Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.
EP. 2: Clinical Implications of a Dose Ranging Study of Ponatinib for CML
Hematologic oncologists summarize the dose ranging study of ponatinib in patients with CML and discuss clinical implications of this work.
EP. 3: Optimal Ponatinib Dose Selection for a Given Patient Population
Dr. Cortes reviews ponatinib dosing strategies based on patient profiles and mutational status.
EP. 4: Efficacy and Toxicity Considerations for Use of Ponatinib
Hagop Kantarjian, MD responds to a review of dosing options in patients with CML treated with ponatinib.
EP. 5: Patient Selection and Dosing of Ponatinib
Jorge E. Cortes, MD and Hagop Kantarjian, MD debate optimal dosing and discuss how they use ponatinib in patients with CML.
EP. 6: Future Implications for Use of Ponatinib
Experts review future implications such as using ponatinib in earlier lines of therapy and in patients with Ph-positive ALL.
EP. 7: Ponatinib Dose-Ranging Study in Chronic-Phase CML: Summary
Jorge E. Cortes, MD and Hagop Kantarjian, MD share a summary on ponatinib in CML and ALL and exploration of potential future studies.
EP. 8: Recap: Finding the Optimal Dose of Ponatinib for Chronic Phase CML
